ClinicalTrials.gg
CompletedNCT03857230Updated Aug 13, 2019Results posted

The Safety and Pharmacokinetics of Primapur and Gonal-f

A Phase 1 interventional study of Follitropin alfa (Primapur) and Follitropin alfa (Gonal-F) in Area Under Curve, Pharmacokinetics and Absorption, sponsored by IVFarma LLC. Completed at 1 site in Russian Federation. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-08-13.

Sponsored by IVFarma LLC · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 3 years 3 months after the study started (first participant enrolled Oct 2015, registered Feb 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

The purpose of the current phase I study was to establish bioequivalence, safety, and tolerance of single 300 IU subcutaneous dose of follitropin alfa biosimilar (Primapur) in comparison to that of reference follitropin alfa preparation (Gonal-F) in healthy young female volunteers.

Read the detailed description

A Phase I, prospective, randomized, open-label, crossover, 2-period, two treatment, clinical study in healthy female volunteers.

Objectives of the study:

  1. To evaluate the frequency and severity of adverse events (AE) following a single 300 IU subcutaneous injection of Primapur (IVFarma, LLC, Russia) and Gonal-F (Merck Serono S.p.A., Italy) to healthy volunteers.
  2. To determine the AUC0-t value of Primapur following a single 300 IU subcutaneous injection to healthy volunteers.
  3. To determine the T½ value of Primapur following a single 300 IU subcutaneous injection to healthy volunteers.
  4. To determine the Сmax value of Primapur following a single 300 IU subcutaneous injection to healthy volunteers.
  5. To determine the Tmax value of Primapur following a single 300 IU subcutaneous injection to healthy volunteers.
  6. To compare the obtained pharmacokinetic characteristics of Primapur and Gonal-F.
02

Conditions studied

  • Area Under Curve
  • Pharmacokinetics
  • Absorption

Keywords

  • follitropin alfa
  • follicle stimulating hormone
  • hormones, hormone substitutes, and hormone antagonists
  • physiological effects of drugs
  • biosimilar
  • bioequivalence
03

In context

Lead sponsor

IVFarma LLC is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy female volunteers aged 18 to 40 years.
  2. (BMI) of 18.5 to 30.0 kg/m2.
  3. Subjects who have used oral for at least 2 menstrual cycles before study entry.
  4. Regular menstruation cycle (24 to 35 days) before initiation of oral contraception.
  5. Presence of both ovaries.
  6. Subjects who are negative for drugs of abuse and alcohol tests at screening.
  7. Subjects who are healthy as validated by pre study medical history, physical examination.
  8. Subjects with acceptable clinical laboratory test results.
  9. A signed form that confirms in writing the volunteer's consent to participate in this clinical study and the volunteer's willingness to comply with all physician recommendations and protocol limitations for the time of participation in the clinical study.
  10. Ability to comply with the requirements of the protocol.
  11. Participants in the study, as well as their sexual partners, are knowledgeable and willing to voluntarily, starting from the week before being included in the study and up to 4 weeks after the last dose of the study drug, and in addition to the contraceptive used, use at least 1 barrier contraceptive method or spermicide.

Exclusion criteria

Exclusion Criteria:

  1. to follitropin alpha, combined oral (ethinylestradiol and drospirenone) or .
  2. Allergy, angioedema (hereditary or idiopathic) in history.
  3. Previous history of ovarian hyperstimulation syndrome (OHSS).
  4. Inability to establish a venous catheter for blood sampling.
  5. Presence of polycystic ovaries (PCO) and ovarian cysts.
  6. Neoplasia and a history of malignant disease.
  7. Deep vein thrombosis, pulmonary embolism.
  8. Subjects with impaired thyroid function.
  9. Regular usage or administration of any drugs, including non-prescription drugs, vitamins, homeopathic remedies and dietary supplements, less than 2 weeks before the study (with the exception of contraceptive pills).
  10. Admission less than 2 months before the start of the study of drugs that have a pronounced effect on hemodynamics, liver function, and medication contained follicle stimulating hormone (FSH), luteinizing hormone (LH), chorionic gonadotropin (hCG), clomiphene, gonadotropin-releasing hormone (GnRH) analogues.
  11. Cardiovascular, bronchopulmonary, nervous, endocrine systems, gastrointestinal tract, liver, kidney, hematopoietic, immune systems, mental diseases.
  12. Acute infectious diseases less than 4 weeks before the start of the study.
  13. Systolic pressure less than 100 mm or above 130 mm Hg; diastolic pressure less than 70 mm or above 90 mm Hg; heart rate less than 60 or more than 80 beats/min.
  14. Blood donation less than 3 months before the start of the study.
  15. Participation in clinical studies of drugs less than 3 months before the start of the present study.
  16. More than 5 alcohol units per week (1 unit is equal to 50 ml of a strong alcoholic drink, 200 ml of dry wine or 500 ml of beer) or anamnestic information about alcoholism, drug addiction, drug abuse.
  17. Smoking more than 5 cigarettes/day.
  18. Narcomania, alcoholism.
  19. Presence of pregnancy.
  20. Lactating.
  21. Any reason that, in the opinion of the investigator, could interfere with safety of the subject or interfere with the objectives of the study.
  22. Subjects with a lactose intolerance, lactase deficiency or glucose-galactose malabsorption.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Sequence A: Primapur - Gonal-F

    Subjects were randomly assigned to receive treatment sequence A: single subcutaneous injection of 300 IU Primapur on study day 1, after 10 days of wash out period a single subcutaneous injection of 300 IU Gonal-F.

    Drug: Follitropin alfa (Primapur) · Drug: Follitropin alfa (Gonal-F)

  • Active comparator
    Sequence B: Gonal-F - Primapur

    Subjects were randomly assigned to receive treatment sequence B: single subcutaneous injection of 300 IU Gonal-F on study day 1, after 10 days of wash out period a single subcutaneous injection of 300 IU Primapur.

    Drug: Follitropin alfa (Primapur) · Drug: Follitropin alfa (Gonal-F)

Interventions

  • During the crossover pharmacokinetic phase, after 42 days of combined oral contraceptive (ethinylestradiol and drospirenone) administration subjects with endogenous level of follicle stimulating hormone (FSH) less than 5 IU/l were randomly assigned to receive one of the following treatment sequences: Sequence A: Single subcutaneous injection of 300 IU Primapur on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Gonal-F. Sequence B: Single subcutaneous injection of 300 IU US Gonal-F on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Primapur.

    Also known as: Follitropin alpha, Follitropin

  • During the crossover pharmacokinetic phase, after 42 days of combined oral contraceptive (ethinylestradiol and drospirenone) administration subjects with endogenous level of follicle stimulating hormone (FSH) less than 5 IU/l were randomly assigned to receive one of the following treatment sequences: Sequence A: Single subcutaneous injection of 300 IU Primapur on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Gonal-F. Sequence B: Single subcutaneous injection of 300 IU US Gonal-F on study day 1, after 10 days of wash out a single subcutaneous injection of 300 IU Primapur.

    Also known as: Follitropin alpha, Follitropin

06

What researchers measure

Primary outcomes

  1. Area Under the Serum Concentration of Follicle Stimulating Hormone (FSH) - Time Curve (AUC(0-192))

    Area under curve (AUC), Time frame: From 0 (predose), 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168 and 192 hours postdose. Blood samples to study the pharmacokinetics are to be collected via a venous catheter, which is placed by means of vein puncture before any injection of r-hFSH. Blood sampling were carried out at certain time points according to the specified scheme: - 20 minutes (20 minutes before the drug injection), 0 hours (immediately prior to injection), and 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168, and 192 hours after each injection of the drug product.

    Time frame: 0-192 hours

  2. Maximum Serum Concentration of Follicle Stimulating Hormone (FSH) (Cmax)

    Maximum serum concentration (Cmax), Time frame: From 0 (predose), 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168 and 192 hours postdose.

    Time frame: 0-192 hours

Secondary outcomes

  1. Time to Reach a Maximum Follicle Stimulating Hormone (FSH) Serum Concentration (Tmax)

    Time to reach a maximum serum concentration (Tmax), Time frame: From 0 (predose), 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168 and 192 hours postdose.

    Time frame: 0-192 hours

  2. Follicle Stimulating Hormone (FSH) Apparent Terminal Half-life (T1/2)

    Terminal half-life (T1/2), Time frame: From 0 (predose), 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168 and 192 hours postdose.

    Time frame: 0-192 hours

Other outcomes

  1. Elimination Rate Constant (Kel)

    Elimination rate constant (Kel): Time frame: From 0 (predose), 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168 and 192 hours postdose.

    Time frame: 0-192 hours

07

Results

Posted Aug 5, 2019

Participant flow

Duration of participation was about 73 days: screening period (up to 7 days), preparation period (up to 28 days), the 1st period (9 days), the 2nd period (9 days), and the follow-up period (28 days starting from the first day of the 2nd period). The wash-out period is 10 days.

Period 1 (Primapur-Gonal-F)
Participant flow — Period 1 (Primapur-Gonal-F)
MilestoneSequence A: Primapur - Gonal-FSequence B: Gonal-F - Primapur
Started1212
Completed1212
Not completed00
Period 2 (Gonal-F-Primapur)
Participant flow — Period 2 (Gonal-F-Primapur)
MilestoneSequence A: Primapur - Gonal-FSequence B: Gonal-F - Primapur
Started1212
Completed1212
Not completed00

Outcome measures

PrimaryArea Under the Serum Concentration of Follicle Stimulating Hormone (FSH) - Time Curve (AUC(0-192))

Area under curve (AUC), Time frame: From 0 (predose), 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168 and 192 hours postdose. Blood samples to study the pharmacokinetics are to be collected via a venous catheter, which is placed by means of vein puncture before any injection of r-hFSH. Blood sampling were carried out at certain time points according to the specified scheme: - 20 minutes (20 minutes before the drug injection), 0 hours (immediately prior to injection), and 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168, and 192 hours after each injection of the drug product.

Time frame:
0-192 hours
Reported as:
Geometric mean · mIU*h/ml
Area Under the Serum Concentration of Follicle Stimulating Hormone (FSH) - Time Curve (AUC(0-192))
mIU*h/mlPrimapurGonal-F
Area Under the Serum Concentration of Follicle Stimulating Hormone (FSH) - Time Curve (AUC(0-192))1202.85 ± 466.281241.01 ± 418.61
Statistical analysis
  • Primapur vs Gonal-F · ANOVA · p = 0.05 · Geometric mean ratio (%): 93.31 · 90% CI 87.25 to 99.79
PrimaryMaximum Serum Concentration of Follicle Stimulating Hormone (FSH) (Cmax)

Maximum serum concentration (Cmax), Time frame: From 0 (predose), 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168 and 192 hours postdose.

Time frame:
0-192 hours
Reported as:
Geometric mean · mIU/ml
Maximum Serum Concentration of Follicle Stimulating Hormone (FSH) (Cmax)
mIU/mlPrimapurGonal-F
Maximum Serum Concentration of Follicle Stimulating Hormone (FSH) (Cmax)14.32 ± 4.7216.00 ± 4.88
Statistical analysis
  • Primapur vs Gonal-F · ANOVA · p = 0.05 · Geometric mean ratio (%): 87.93 · 90% CI 82.85 to 93.33
SecondaryTime to Reach a Maximum Follicle Stimulating Hormone (FSH) Serum Concentration (Tmax)

Time to reach a maximum serum concentration (Tmax), Time frame: From 0 (predose), 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168 and 192 hours postdose.

Time frame:
0-192 hours
Reported as:
Mean · hours
Time to Reach a Maximum Follicle Stimulating Hormone (FSH) Serum Concentration (Tmax)
hoursPrimapurGonal-F
Time to Reach a Maximum Follicle Stimulating Hormone (FSH) Serum Concentration (Tmax)18.70 ± 5.7719.22 ± 4.93
SecondaryFollicle Stimulating Hormone (FSH) Apparent Terminal Half-life (T1/2)

Terminal half-life (T1/2), Time frame: From 0 (predose), 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168 and 192 hours postdose.

Time frame:
0-192 hours
Reported as:
Geometric least squares mean · hours
Follicle Stimulating Hormone (FSH) Apparent Terminal Half-life (T1/2)
hoursPrimapurGonal-F
Follicle Stimulating Hormone (FSH) Apparent Terminal Half-life (T1/2)70.78 ± 32.5471.71 ± 33.47
Other pre-specifiedElimination Rate Constant (Kel)

Elimination rate constant (Kel): Time frame: From 0 (predose), 1, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 120, 168 and 192 hours postdose.

Time frame:
0-192 hours
Reported as:
Mean · 1/h
Elimination Rate Constant (Kel)
1/hPrimapurGonal-F
Elimination Rate Constant (Kel)0.01 ± 0.0030.01 ± 0.006

Adverse events

Collected over From the study day 1 to day 56.. Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Primapur0/24 (0%)0/24 (0%)11/24 (45.8%)
Gonal-F0/24 (0%)0/24 (0%)10/24 (41.7%)
Most frequent other events
Most frequent other events
EventPrimapurGonal-F
Laboratory investigationsInvestigations8/248/24
HeadacheNervous system disorders2/243/24
NauseaGastrointestinal disorders1/241/24
VomitingGastrointestinal disorders0/241/24

Baseline characteristics

Women aged 18 to 40 years; body mass index (BMI) of 18.5 to 30 kg/m2

Age, Categorical
Age, Categorical(Participants)Sequence A: Primapur - Gonal-FSequence B: Gonal-F - PrimapurTotal
Periods 1 and 2 — <=18 years000
Periods 1 and 2 — Between 18 and 65 years121224
Periods 1 and 2 — >=65 years000
Age, Continuous
Age, Continuous(years)Sequence A: Primapur - Gonal-FSequence B: Gonal-F - PrimapurTotal
Mean29.92 ± 4.2726.58 ± 3.1228.25 ± 4.04
Sex: Female, Male
Sex: Female, Male(Participants)Sequence A: Primapur - Gonal-FSequence B: Gonal-F - PrimapurTotal
Female121224
Male000
Region of Enrollment
Region of Enrollment(Participants)Sequence A: Primapur - Gonal-FSequence B: Gonal-F - PrimapurTotal
Russia121224
Body mass index (BMI)
Body mass index (BMI)(kg per m2)Sequence A: Primapur - Gonal-FSequence B: Gonal-F - PrimapurTotal
Mean23.41 ± 3.5322.41 ± 2.8022.91 ± 3.16
08

Study locations

1 site
  • O.M. Filatov Municipal Clinical Hospital N 15
    Moscow, Russian Federation
09

References and documents

Publications

  • Tyul'kina EE, Gordeev IG, Grebenkin DYu, Kazei VA, Tsikarishvili MM, Luchinkina EE, et al. Randomized crossover comparative study of safety, tolerance and pharmacokinetics of Primapur vs. Gonal-f upon single-dose subcutaneous administration in healthy volunteers. Eksperimental'naya i Klinicheskaya Farmakologiya. 2017; 80(4): 13-17 (in Russian).

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2015 to primary completion in May 2016, 6 months.

Results were first posted in Aug 2019, 3 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2019
First posted
Feb 27, 2019
StartActual
Oct 29, 2015
Primary completionActual
May 10, 2016
CompletionActual
May 10, 2016
Results first posted
Aug 5, 2019
Last update
Aug 13, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03857230
Lead sponsor
IVFarma LLC
Collaborators
NADIM LLC
Responsible party
Sponsor
First posted
Feb 27, 2019
Start date
Oct 29, 2015
Primary completion
May 10, 2016
Completion
May 10, 2016
Results posted
Aug 5, 2019
Last update
Aug 13, 2019

Study contacts

Ivan G Gordeev, D.Sc., MD
principal investigator · O.M. Filatov Municipal Clinical Hospital N 15

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Follitropin alfa

Start the discussion